Business NewsPR NewsWire • Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research

Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research

Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research

WESTON, Fla., Dec. 18, 2015 /PRNewswire/ -- Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement...

View More : http://www.prnewswire.com/news-releases/variant-pharmaceuticals-licenses-worldwide-rights-to-asset-targeted-to-treat-rar...
Releted News by prnewswire
MUJOSH Expands into the Australian Market as it Celebrates The Grand Opening in Melbourne
MedGenome Now Offering Panorama™ NIPT in India via Natera's Constellation™ Cloud-based Software Platform
Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research